Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis

The glucagon receptor antagonist (GRA) volagidemab is the first‐in‐class fully human monoclonal antibody that inhibits glucagon receptor. GRA can improve glycemia by reducing endogenous glucose production and reduce risks of diabetic ketoacidosis by suppressing ketogenesis. This systematic review an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the New York Academy of Sciences 2025-01, Vol.1543 (1), p.94-101
Hauptverfasser:	Dutta, Deep, Kamrul‐Hasan, A. B. M., Surana, Vineet, Singla, Rajiv, Khandelwal, Deepak, Aggarwal, Sameer, Nagendra, Lakshmi, Bhattacharya, Saptarshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Blood Blood glucose Blood Glucose - drug effects Clinical trials Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Effectiveness Glucagon Glucose Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin insulin requirement Ketoacidosis Ketogenesis Meta-analysis Monoclonal antibodies Placebos Randomized Controlled Trials as Topic Receptors Receptors, Glucagon - antagonists & inhibitors Risk reduction Systematic review Treatment Outcome type‐1 diabetes volagidemab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!